ClinicalTrials.gov Compliance Update

Aug 1, 2021 | Conduits News

As part of The ISMMS CTSA ConduITS mission to streamline and centralize the infrastructure needed to accelerate translational research across an ever-expanding research enterprise, ConduITS and the Office of Research Services directs Investigators to resources and support related to scientific regulatory and reporting requirements which also includes the Research Roadmap.

As public awareness increases, more people are looking at clinical trials outcomes for information regarding efficacy and safety of therapies. The importance of posting of clinical trial information in a timely manner allowing for transparency of research study outcomes, broadening scientific knowledge for providers and other researchers, as well as enabling public trust of patients and volunteers cannot be underscored enough.

In the summer of 2020, Pre-Notice of Noncompliance letters were sent to Principal Investigators for studies registered on ClinicalTrials.gov, which is managed by NIH/NLM, who did not comply with their legal reporting obligation.  In April 2021, the FDA issued about 40 Notice of Noncompliance letters giving responsible parties 30 days to meet their obligations or face penalties which can include, but are not limited to, monetary penalties, withholding of current or future grants, rejection of manuscripts for journal publication, and notice of noncompliance posted to the FDA’s website and on ClinicalTrials.gov.

During this period, nationwide, research institutions have improved in compliance with number of trials registered increasing and number of trials with unreported results decreasing. At ISMMS, investigators are involved in robust research clinical trials across all specialties and understand the importance of reporting results for the benefit of colleagues, the research community, and the public.

Please refer to the Research Roadmap for step-by-step guidance on ClinicalTrials.gov requirements or if you have questions please a Research 411 help desk ticket with The Office or Research Services.

ConduITS is supported by NCATS of the NIH’s CTSA Program. Any use of CTSA-supported resources requires citation of grant number UL1TR001433 awarded to ISMMS in the acknowledgment section of every publication resulting from this support. Adherence to the NIH Public Access Policy is also required.

 

Recent ConduITS News

What does the Innovation Core do?

Mount Sinai’s Innovation Core is designed to fill the gap in the training and expertise needed to move a discovery from the research setting into a commercially viable product, or to recognize the potential for commercialization. i3 Prism i3 Prism is an early-stage...

read more

What is the Innovation Core?

Mount Sinai’s Innovation Partners (MSIP) is the technology commercialization arm of the Mount Sinai Health System, responsible for driving the real-world application of Mount Sinai discoveries and inventions, and the development of research partnerships with industry....

read more

Newsletter Special Edition

Click here to view the special edition of the Conduit Newsletter, designed in CANVA! As part of a new initiative by The Mount Sinai ConduITS Institutes for Translational Sciences (CTSA), we are thrilled to introduce our latest newsletter designed to aid researchers in...

read more

Trainee Corner

Mount Sinai CTSA Featured Trainees

Megan Januska

Megan Januska

Megan Januska, MD is an Assistant Professor in the Division of Pediatric Pulmonology in the Jack and Lucy Clark Department of Pediatrics and in the Department of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai and Mount Sinai Kravis...

read more
Sangeetha Vadakke-Madathil

Sangeetha Vadakke-Madathil

Sangeetha Vadakke-Madathil, PhD, is currently a junior faculty (Instructor of Medicine) at Icahn School of Medicine at Mount Sinai, New York, NY. After receiving her Ph.D. degree in human hematopoietic stem cells and transplant biology from National Centre for Cell...

read more